Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy

Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, Völkl S, Mackensen A, Schett G, Basu S (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 31

Article Number: 101104

DOI: 10.1016/j.omtm.2023.08.023

Abstract

Chimeric antigen receptor (CAR) T cells targeting CD19⁺ B cells have demonstrated efficacy in refractory systemic lupus erythematosus (SLE). Although initial clinical data suggest that anti-CD19 CAR T cell therapy is well tolerated and highly effective, the immunologic consequences of CAR T cell therapy in SLE patients remain unclear. We profiled serum in six refractory SLE patients prior to and 3 months following CAR T cell infusion. Three months post T cell infusion, the inflammatory cytokines IL-6 and TNFα decreased in patient sera. This was accompanied by elevations in serum IL-7 and BAFF. Furthermore, SLE-associated antibodies dropped profoundly in five of six patients. Last, consistent with other reports of CD19 CAR T therapy in B cell malignancies, we were able to show marginal impact of anti-CD19 CART therapy on pre-existing humoral immune responses in SLE patients. Together, these results provide insights into the mechanisms of efficacy of anti-CD19 CAR T cell therapy in SLE.

Authors with CRIS profile

Involved external institutions

Cabaletta Bio Inc United States (USA) (US)

How to cite

APA:

Nunez, D., Patel, D., Volkov, J., Wong, S., Vorndran, Z., Müller, F.,... Basu, S. (2023). Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Molecular Therapy, 31. https://doi.org/10.1016/j.omtm.2023.08.023

MLA:

Nunez, Daniel, et al. "Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy." Molecular Therapy 31 (2023).

BibTeX: Download